In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews, May 2014

Executive Summary

This Month's Profile Group, Medtech Start-Ups Innovate In Minimally Invasive Gynecology, features profiles of Channel Medsystems, EmboMedics, and Minerva Surgical. Plus these Start-Ups Across Health Care: Ginolis, Peptineo, Silk Road Medical, and Somersault Orthopedics.

You may also be interested in...

Medtech Start-Ups Innovate In Minimally Invasive Gynecology

Medtech start-ups are taking on the global endometrial ablation and uterine artery embolization markets with next-generation systems designed to raise the standard of care in menorrhagia treatment. Profiles of Channel Medsystems, EmboMedics, and Minerva Surgical.

Minerva Surgical Inc.

Hologic’s NovaSure system has been able to maintain a substantial lead in the US global endometrial ablation market, but Minerva Surgical Inc. is looking to change all that with its effective, easy-to-use RF argon plasma energy-based Minerva Endometrial Ablation System. What makes this competitive scenario especially intriguing is that three of Minerva's founders and eight of its board members were also closely aligned with Novacept, which developed NovaSure.

EmboMedics Inc.

EmboMedics Inc. has developed a bioresorbable embolic bead technology to treat uterine fibroids without causing long-term side effects. Currently in preclinical testing, EmboMedics' technology will initially be used in the treatment of uterine fibroids, although its potential for controlled and predictable drug release could lend itself to a variety of other acute and chronic indications, including liver and prostate cancer, trauma, and obesity.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts